Isis Pharmaceuticals, Inc. Form 10K - page 118

Outstanding EquityAwards at Fiscal Year-End – Directors
The following table shows for the fiscal year ended December 31, 2014, certain information regarding
outstanding awards at fiscal year-end of all our non-employee Directors:
Outstanding EquityAwards At December 31, 2014
OptionAwards
StockAwards
Name
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
(1)
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
Option
Exercise
Price
($)
Option
Expiration
Date
Number of
Shares or
Units of Stock
that Have Not
Vested
(2) (3)
Market Value
of Shares or
Units of Stock
that Have Not
Vested
(4)
($)
Spencer R. Berthelsen. . . . . . . . . . . . .
10,000
0
$ 3.95 6/30/15
4,697
$ 289,993
12,500
0
$ 5.93 7/2/16
12,500
0
$ 9.77 7/1/17
15,000
0
$13.88 6/30/18
15,000
0
$16.32 6/30/19
15,000
0
$ 9.22 6/30/20
11,250
3,750
$ 9.30 6/30/21
5,626
5,624
$12.94 7/1/22
2,813
8,437
$28.47 6/30/23
0
16,000
$35.53 6/30/24
Breaux B. Castleman . . . . . . . . . . . . .
5,625
16,875
$26.66 6/24/23
6,885
$ 425,080
2,813
8,437
$28.47 6/30/23
0
16,000
$35.53 6/30/24
Joseph Klein . . . . . . . . . . . . . . . . . . .
3,750
0
$ 9.22 6/30/20
4,697
$ 289,993
3,750
$ 9.30 6/30/21
2,813
5,624
$12.94 7/1/22
2,813
8,437
$28.47 6/30/23
0
16,000
$35.53 6/30/24
Joseph Loscalzo . . . . . . . . . . . . . . . . .
0
22,500
$49.09 2/2/24
6,417
$ 396,186
0
16,000
$35.53 6/30/24
Frederick T. Muto . . . . . . . . . . . . . . .
10,000
0
$ 3.95 6/30/15
4,697
$ 289,993
12,500
0
$ 5.93 7/2/16
12,500
0
$ 9.77 7/1/17
15,000
0
$13.88 6/30/18
15,000
0
$16.32 6/30/19
15,000
0
$ 9.22 6/30/20
11,250
3,750
$ 9.30 6/30/21
5,626
5,624
$12.94 7/1/22
2,813
8,437
$28.47 6/30/23
0
16,000
$35.53 6/30/24
Joseph H. Wender . . . . . . . . . . . . . . .
10,000
0
$ 3.95 6/30/15
4,697
$ 289,993
12,500
0
$ 5.93 7/2/16
12,500
0
$ 9.77 7/1/17
15,000
0
$13.88 6/30/18
15,000
0
$ 9.22 6/30/20
11,250
3,750
$ 9.30 6/30/21
5,626
5,624
$12.94 7/1/22
2,813
8,437
$28.47 6/30/23
0
16,000
$35.53 6/30/24
(1) The options were granted out of our Directors’ Plan and have a term of ten years and vest at the rate of 25%per year over four years.
(2) The RSUs were granted out of our Directors’ Plan and vest at the rate of 25%per year over four years.
(3) All of our non-employee Directors are subject to our Stock Holding and Ownership Guidelines for RSU Shares, which requires each
non-employee Director to accumulate and maintain shares of Common Stock issued pursuant to RSUs until he has accumulated shares
of Common Stock equal to four times such non-employee Director’s base annual cash retainer for service as a Director (but not for
service on a Board committee), or until his termination of service.
(4) Market value of stock awards was determined by multiplying the number of unvested shares by $61.74, which was the closing market
price of our common stock on the Nasdaq Select Market on December 31, 2014, the last trading day of fiscal 2014.
118
I...,108,109,110,111,112,113,114,115,116,117 119,120,121,122,123,124,125,126,127,128,...186
Powered by FlippingBook